Genes encoding the histone H3 lysine 4 methyltransferases KMT2C and KMT2D are subject to deletion and mutation in pancreatic ductal adenocarcinoma (PDAC), where these lesions identify a group of patients with a more favorable prognosis. In this study, we demonstrate that low KMT2C and KMT2D expression in biopsies also defines better outcome groups, with median survivals of 15.9 versus 9.2 months (P ¼ 0.029) and 19.9 versus 11.8 months (P ¼ 0.001), respectively. Experiments with eight human pancreatic cell lines showed attenuated cell proliferation when these methyltransferases were depleted, suggesting that this improved outcome may reflect a cell-cycle block with diminished progression from G 0 -G 1 . RNA-seq analysis of PDAC cell lines following KMT2C or KMT2D knockdown identified 31 and 124 differentially expressed genes, respectively, with 19 genes in common. Gene-set enrichment analysis revealed significant downregulation of genes related to cell-cycle and growth. These data were corroborated independently by examining KMT2C/D
<p>Analysis of PDAC tumors from the ICGA and TCGA datasets suggests that lower KMT2C and KMT2D expression may correlate with improved patient survival.</p>
<p>Confirmation of gene knockdown at the exon level, and correlations between the multiple siRNAs, for both KMT2C and KMT2D within the RNA-seq data.</p>
<p>Changes in RPKM expression for selected genes identified by RNA-seq, and global levels of H3K4 methylation, following depletion of KMT2D or KMT2C by siRNA.</p>
<p>Depletion of Kmt2d and Kmt2c does not affect the viability of murine pancreatic cancer cells, and Kmt2c depletion does not affect sensitivity to 5FU.</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.